Echopoint Medical, a UCL spinout, has developed the iKOr system, a proprietary diagnostic solution intended to enhance precision, ease and reliability of coronary flow assessments. The system is aimed at facilitating early intervention and better management of angina, with particular emphasis on improving diagnosis in women. The company completed a 10‑patient clinical trial at Bart’s Hospital in London. Echopoint is using its recent funding to advance the iKOr through the FDA approval process and prepare for a US market debut. The company positions the iKOr to accelerate adoption of key diagnostic indicators in interventional cardiology. The Series A infusion signals a move from university research toward commercialisation and US market entry. Echopoint Medical is a UCL spinout that develops microcatheters with fibre‑optic sensors to accurately measure blood pressure and flow. Its technology platform translates ultrasound signals from those sensors into clinically meaningful metrics. The product targets coronary heart disease patients in a ‘grey zone’ where treatment need is unclear, aiming to enable more precise assessment and substantially reduce unnecessary stent implants. The company intends to use the new funds to further develop its optical fibre sensors and the signal‑translation platform. Echopoint was founded in November 2018 and is based in London, UK. The leadership team includes executive chairman Antony Odell, CTO Dr Adrien Desjardins and CMO Dr Malcolm Finlay.

Total raised

$9M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2024